Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
C. A. Higgins, B. E. Nilsson-Payant, A. Kurland…·J. R. Johnson
This study identifies p38β as a critical host factor for SARS-CoV-2 replication and shows that inhibiting it reduces viral replication and cytokine production.
B. E. Nilsson-Payant, B. R. tenOever, A. J. W. te Velthuis
This study demonstrates that ANP32A is essential for both vRNA and cRNA synthesis in influenza A virus replication, challenging previous assumptions about its role.
V. Gopal, B. E. Nilsson-Payant, H. French…·A. J. W. te Velthuis
This study shows that zinc-embedded PA66 fabrics absorb and inactivate SARS-CoV-2 and influenza A virus, with stable performance after multiple washes.
T. M. Yaron, B. E. Heaton, T. M. Levy…·M Kavanagh-Williamson
This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.
Y. Han, L. Yang, X. Duan…·S. Chen
This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.
L. Si, H. Bai, M. Rodas…·D. E. Ingber
This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.
D. Blanco-Melo, B. E. Nilsson-Payant, S. Uhl…·B. tenOever
The paper shows that limiting nucleoprotein (NP) in negative-sense RNA viruses leads to defective genomes and triggers host interferon responses, making NP a key antiviral target.